AJ Vaccines A/S news
AJ Vaccines’ production site-facility in Copenhagen, Denmark has been approved by the Gulf Health Council (GHC) effective 9 November 2020. The approval indicates the vaccine production is at a high standard which will help to secure timely patient access to vaccines in the Gulf Cooperation Council (GCC) countries and wider Middle Eastern region.
In recent years, the regulatory requirements for vaccine registration have become increasingly sophisticated in the GCC countries, name
International vaccine manufacturer, AJ Vaccines has received WHO prequalification for Picovax®, the first stand-alone dose sparing Inactivated Polio Vaccine (IPV) on 21st April 2020. First deliveries to UN agencies such as UNICEF and PAHO are expected by mid-2020.
COPENHAGEN, 22 April 2020 – Despite ongoing concerted efforts to eradicate polio, it appears to be on the rise again with more cases registered in 2019 than 2018. Looking ahead, AJ Vaccines’ d
AJ Vaccines today announced that its adjuvanted IPV vaccine Picovax® has gained marketing approval in Denmark by the Danish Medicines Agency. The approval process was initiated in 2018 following positive results from clinical trials involving almost 3,000 infants. The Danish marketing approval paves the way for WHO prequalification with a view to enable AJ Vaccines to deliver Picovax® doses to UN agencies such as UNICEF and PAHO early next year.
The marketing approval of the a
AJ Vaccines has initiated a total reconstruction and expansion of its existing Polio vaccine production facilities. The new facilities will increase production capacity substantially while simultaneously ensuring compliance with future WHO demands for Polio vaccine production and containment.
AJ Vaccines and the company’s owner have decided to initiate a comprehensive and needed upgrade of the production facilities in Copenhagen – not least